Cargando…
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
The recognition of homologous recombination deficiency (HRD) as a frequent feature of high-grade serous ovarian cancer (HGSOC) has transformed treatment paradigms. Poly(ADP-ribose) polymerase inhibitors (PARPis), developed based on the rationale of synthetic lethality that predicates antitumor effic...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141874/ https://www.ncbi.nlm.nih.gov/pubmed/34015643 http://dx.doi.org/10.1016/j.esmoop.2021.100144 |